These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29779045)

  • 41. Diagnostic value of brain MRI and 18F-FDG PET in the differentiation of Parkinsonian-type multiple system atrophy from Parkinson's disease.
    Kwon KY; Choi CG; Kim JS; Lee MC; Chung SJ
    Eur J Neurol; 2008 Oct; 15(10):1043-9. PubMed ID: 18717730
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of an optimized [
    Caminiti SP; Alongi P; Majno L; Volontè MA; Cerami C; Gianolli L; Comi G; Perani D
    Eur J Neurol; 2017 May; 24(5):687-e26. PubMed ID: 28244178
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of 18F-FDG-PET image reconstruction algorithms on the expression of characteristic metabolic brain network in Parkinson's disease.
    Tomše P; Jensterle L; Rep S; Grmek M; Zaletel K; Eidelberg D; Dhawan V; Ma Y; Trošt M
    Phys Med; 2017 Sep; 41():129-135. PubMed ID: 28188080
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical impact of dual-tracer FDOPA and FDG PET/CT for the evaluation of patients with parkinsonian syndromes.
    Emsen B; Villafane G; David JP; Evangelista E; Chalaye J; Lerman L; Authier FJ; Gracies JM; Itti E
    Medicine (Baltimore); 2020 Nov; 99(45):e23060. PubMed ID: 33157962
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Magnetic Resonance Parkinsonism Index and midbrain to pons ratio: Which index better distinguishes Progressive Supranuclear Palsy patients with a low degree of diagnostic certainty from patients with Parkinson Disease?
    Nigro S; Morelli M; Arabia G; Nisticò R; Novellino F; Salsone M; Rocca F; Quattrone A
    Parkinsonism Relat Disord; 2017 Aug; 41():31-36. PubMed ID: 28487107
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuroimaging in Parkinson's Disease: necessity or exaggeration?
    Śmiłowska K; Burzyńska-Makuch M; Brockhuis B; Piekarski R; Friedman A; Popek A; Sławek J
    Neurol Neurochir Pol; 2021; 55(6):536-548. PubMed ID: 34637136
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease.
    Agosta F; Altomare D; Festari C; Orini S; Gandolfo F; Boccardi M; Arbizu J; Bouwman F; Drzezga A; Nestor P; Nobili F; Walker Z; Pagani M;
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1546-1556. PubMed ID: 29717332
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Role of Single-Subject Brain Metabolic Patterns in the Early Differential Diagnosis of Primary Progressive Aphasias and in Prediction of Progression to Dementia.
    Cerami C; Dodich A; Greco L; Iannaccone S; Magnani G; Marcone A; Pelagallo E; Santangelo R; Cappa SF; Perani D
    J Alzheimers Dis; 2017; 55(1):183-197. PubMed ID: 27662315
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Not Available].
    Prange S; Hermier M; Danaila T; Laurencin C; Thobois S
    Presse Med; 2017 Mar; 46(2 Pt 1):202-209. PubMed ID: 28040345
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting.
    Perani D; Della Rosa PA; Cerami C; Gallivanone F; Fallanca F; Vanoli EG; Panzacchi A; Nobili F; Pappatà S; Marcone A; Garibotto V; Castiglioni I; Magnani G; Cappa SF; Gianolli L;
    Neuroimage Clin; 2014; 6():445-54. PubMed ID: 25389519
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PET and the investigation of dementia in the parkinsonian patient.
    Turjanski N; Brooks DJ
    J Neural Transm Suppl; 1997; 51():37-48. PubMed ID: 9470127
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Imaging in Parkinson's disease.
    Pagano G; Niccolini F; Politis M
    Clin Med (Lond); 2016 Aug; 16(4):371-5. PubMed ID: 27481384
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder.
    Meles SK; Vadasz D; Renken RJ; Sittig-Wiegand E; Mayer G; Depboylu C; Reetz K; Overeem S; Pijpers A; Reesink FE; van Laar T; Heinen L; Teune LK; Höffken H; Luster M; Kesper K; Adriaanse SM; Booij J; Leenders KL; Oertel WH
    Mov Disord; 2017 Oct; 32(10):1482-1486. PubMed ID: 28734065
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Automatic classification of idiopathic Parkinson's disease and atypical Parkinsonian syndromes combining [
    Martins R; Oliveira F; Moreira F; Moreira AP; Abrunhosa A; Januário C; Castelo-Branco M
    J Neural Eng; 2021 Apr; 18(4):. PubMed ID: 33848996
    [No Abstract]   [Full Text] [Related]  

  • 55. Diagnostic Utility of [11C]DTBZ Positron Emission Tomography In Clinically Uncertain Parkinsonism: Experience of a Single Tertiary Center.
    Pérez-Lohman C; Kerik NE; Díaz-Meneses IE; Cervantes-Arriaga A; Rodríguez-Violante M
    Rev Invest Clin; 2018; 70(6):285-290. PubMed ID: 30532098
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia.
    Bouwman F; Orini S; Gandolfo F; Altomare D; Festari C; Agosta F; Arbizu J; Drzezga A; Nestor P; Nobili F; Walker Z; Morbelli S; Boccardi M;
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1526-1533. PubMed ID: 29744573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Role of Tau Imaging in Parkinsonian Disorders.
    Hammes J; Drzezga A; van Eimeren T
    Curr Neurol Neurosci Rep; 2018 Oct; 18(12):86. PubMed ID: 30293094
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Additional Value of Early-Phase 18F-FP-CIT PET Image for Differential Diagnosis of Atypical Parkinsonism.
    Jin S; Oh M; Oh SJ; Oh JS; Lee SJ; Chung SJ; Kim JS
    Clin Nucl Med; 2017 Feb; 42(2):e80-e87. PubMed ID: 27922865
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.
    Buchert R; Buhmann C; Apostolova I; Meyer PT; Gallinat J
    Dtsch Arztebl Int; 2019 Nov; 116(44):747-754. PubMed ID: 31774054
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolic pattern analysis of
    Gu SC; Ye Q; Yuan CX
    Rev Neurosci; 2019 Oct; 30(7):743-756. PubMed ID: 31050657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.